Bioventus (BVS) Other Non-Current Assets (2021 - 2022)
Bioventus' (BVS) quarterly Other Non-Current Assets came in at $406.0 million in Q4 2022, up 711.99% on a YoY basis from $50.0 million in Q4 2021, and up 711.99% quarter-over-quarter from $50.0 million in Q2 2022.
Powered by 
Analysis
Bioventus (BVS) Other Non-Current Assets (2021 - 2022) Analysis & Trends
Bioventus (BVS) has reported Other Non-Current Assets for 2 consecutive years, with $406.0 million the latest figure, recorded in Q4 2022.
- For the quarter ending Q4 2022, Other Non-Current Assets rose 711.99% year-over-year to $406.0 million; the trailing twelve-month figure through Dec 2022 stood at $406.0 million (up 711.99% YoY), and the FY2022 full-year result was $406.0 million, up 711.99% from the prior year.
- Other Non-Current Assets grew to $406.0 million in Q4 2022 per BVS's latest filing, from $50.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $406.0 million in Q4 2022 and bottomed at $50.0 million in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | - |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 4.32 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 3.23 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 45.22 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 616.40 Mn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 434.00 Mn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 273.70 Mn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 215.10 Mn |
| 10 | Bioventus | 923.70 Mn | 894.24 Mn | 105.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2022 | 405.99 Mn |
| Apr 2, 2022 | 50.00 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Oct 2, 2021 | 50.00 Mn |